Mission Impacts
This investment will see the ambitious gut health biopharma business expand and accelerate its work, broadening its research and development (R&D) programme and facilitating new clinical trials that will add significantly to the quantity and quality of the data it gathers.
About EnteroBiotix
EnteroBiotix is carrying out clinical trials of drugs designed to prevent and treat a range of conditions including cancer, liver cirrhosis, and irritable bowel syndrome (IBS).
“Its drug manufacturing technology aligns with the Bank’s mission of harnessing innovation. Our investment of £6 million, as part of a larger total funding package, is a major step forward for the company as it accelerates the pace to develop treatments that will ultimately provide great relief to patients living with a range of conditions.
“We are proud to support this innovative company achieve its ambitions to deliver treatment to patients on a global scale."
Key Information
Alignment to the United Nation's Sustainable Development Goals
Good Health and Well-being
Decent Work and Economic Growth
Industry, Innovation and Infrastructure
Key Quote
Dr James McIlroy, EnteroBiotix chief executive, said: “This funding is further endorsement of EnteroBiotix and our vision of creating treatments that can have a global impact. Our facility in Bellshill is one of the most advanced of its kind in Europe and ensures safe and consistent in-house manufacturing.
“The support from the Scottish National Investment Bank means we can invest in our R&D programme, our team, and our facilities, all of which means we can develop treatments at a faster pace. Our long-term mission to transform the standard of care for patients suffering from high unmet clinical needs associated with the gut microbiome.
“Scotland’s life sciences sector is a growing industry, and with the Bank’s backing we can also contribute to improving skills and enhancing knowledge.”
